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Amyloid pathologyRecently, Aβ peptide variantswith anN-terminal truncation andpyroglutamatemodiﬁcationwere identiﬁedand
shown to be highly neurotoxic and prone to aggregation. This modiﬁcation of Aβ is catalyzed by glutaminyl
cyclase (QC) and pharmacological inhibition of QC diminishes Aβ deposition and accompanying gliosis and
ameliorates memory impairment in transgenic mouse models of Alzheimer's disease (AD). QC expression was
initially described in the hypothalamus, where thyrotropin-releasing hormone (TRH) is one of its physiological
substrates. In addition to its hormonal role, a novel neuroprotective function of TRH following excitotoxicity
and Aβ-mediated neurotoxicity has been reported in the hippocampus. Functionally matching this ﬁnding, we
recently demonstrated QC expression by hippocampal interneurons in mouse brain.
Here, we detected neuronal co-expression of QC and TRH in the hippocampus of young adult wild type mice
using double immunoﬂuorescence labeling. This provides evidence for TRH being a physiological QC substrate
in hippocampus. Additionally, in neocortex of aged but not of young mice transgenic for amyloid precursor
protein an increase of QC mRNA levels was found compared to wild type littermates. This phenomenon was
not observed in hippocampus, which is later affected by Aβ pathology. However, in hippocampus of transgenic —
but not of wild type mice — a correlation between QC and TRH mRNA levels was revealed. This co-regulation of
the enzyme QC and its substrate TRH was reﬂected by a co-induction of both proteins in reactive astrocytes in
proximity of Aβ deposits. Also, in primary mouse astrocytes a co-induction of QC and TRH was demonstrated
upon Aβ stimulation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is characterized by the formation of Aβ
plaques and neuroﬁbrillary tangles [1,2]. In particular neocortex and
hippocampus are affected by AD pathology leading to clinical symptoms
like cognitive decline and loss of memory function [2–4]. The knowledge
about the structural diversity of Aβ peptides was extended in the 1990s
by the identiﬁcation of N-terminally truncated and pyroglutamateprecursor protein; BACE1, beta-
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e (H.-U. Demuth),(pGlu)-modiﬁed Aβ peptides (pGlu-Aβ) in post mortem brains of AD
patients [5,6]. These pGluAβ-peptides exhibit altered biochemical prop-
erties causing increased neurotoxicity, resistance to proteolysis and
accelerated tendency to aggregate [7–10].
Subsequently, the enzyme glutaminyl cyclase (QC)was demonstrated
to catalyze this post-translational modiﬁcation of Aβ in vitro [11] and
in vivo [12]. Furthermore, pharmacological inhibition of QC leads to a
signiﬁcant reduction of overall Aβ aggregation in transgenic animal
models of AD and to better performance in experimental tasks of learning
and memory [12].
Recently, we reported QC expression in a subset of hippocampal
interneurons of wild type mice [13] as well as deposition of pGlu-Aβ
in the core of Aβ plaques in human amyloid precursor protein (APP)
transgenic Tg2576 mice [14]. An understanding of the physiological
function and substrate speciﬁcity of QC in brain regions such as the
hippocampus appears important in order to (i) gain insight into the in-
volvement of QC in AD-related pathological changes and (ii) estimate
the effects of pharmacological inhibition of QC in the course of a possible
therapeutic intervention.
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mus, where the enzyme catalyzes the pGlu modiﬁcation of neuropep-
tides like neurotensin and thyrotropin-releasing hormone (TRH)
[15–17]. Notably, QC-mediated pGlu modiﬁcation of TRH is known to
occur as the latest step of a processing cascade which is essential for
the biological activity of TRH enabling its interaction with speciﬁc TRH
receptors in pituitary gland and decreasing its degradation rate
[18–21]. In this hypothalamus–pituitary–thyroid (HPT) axis, activation
of TRH receptors increases the release of TSH, which in turn stimulates
the secretion of thyroid hormones [22]. Accordingly, QC knock-out
mice show reduced plasma thyroxine concentration [23].
However, there is evidence for a function of TRH independent of the
HPT axis. In this context, TRHwas shown to exhibit neuromodulatory as
well as neuroprotective effects. The expression of TRH in hippocampus,
raphe nuclei and the hypothalamic nuclei [24–27] as well as the co-
localization with neurotransmitters like choleocystokinin, galanin,
neuropeptide Y and serotonin point towards a function of TRH as
neuromodulator [25,28–30]. More recently, the potential of TRH to act
as a neuroprotective compound has been discussed. TRH was reported
to prevent neurodegenerative effects of excitotoxic substances like
kainate, glutamate and NMDA in cell culture studies of organotypic
brain slices and primary neurons [31–33]. In this context, it is also notable
that TRH decreases the release of excitatory glutamate [34] but increases
secretion of inhibitoryGABA [35] as shown in electrophysiological studies
using organotypic brain slice cultures and primary neurons.
Interestingly, TRH-mediated neuroprotection has not only been
reported with respect to excitotoxicity [31–33], Parkinson's disease [36,
37] and following brain injury [38,39], but also in response to Aβ neuro-
toxicity [39,40]. Furthermore, in post mortem hippocampal tissue of AD
patients diminished levels of TRH were demonstrated and depletion of
TRH in cell culture studies was shown to result in hyperphosphorylation
of tau [41], another hallmark of AD.
In summary, due to its presumedneuroprotective effects, hippocam-
pal TRH expression and function deserves a thorough investigation,
especially since the TRH-modifying enzyme QC also contributes to Aβ
pathology. In order to study a possible spatial and temporal relationship
betweenhippocampal QC and TRHexpression, quantitativemRNA anal-
ysis and immunohistochemical labeling were performed in young and
aged wild type and Tg2576 mice with distinct hippocampal Aβ pathol-
ogy. Additionally, activated astrocytes were used as an in vitromodel to
study a possible co-regulation of QC and TRH under pathogenic condi-
tions. The relevance of TRH in the hippocampus, a brain area of particu-
lar importance in learning andmemorywhich is strongly affected in AD,
is discussed.
2. Materials and methods
2.1. Experimental animals
In order to analyze hippocampal QC and TRH expression, transgenic
Tg2576 mice and wild type littermates at postnatal ages of 4, 8, 10, 13,
17 and 21 months were used for immunohistochemical and for qPCR
experiments (N = 3–6 per age group). Due to overexpression of
human APP comprising Swedish double mutation (Lys670→Asn,
Met671→Leu) Tg2576 mice develop Aβ pathology ﬁrst detectable by
10 months of age in entorhinal cortex and by about 13 months in
hippocampus.
2.2. Preparation of mouse brains for immunohistochemistry and qPCR
The mice were deeply anesthetized with pentobarbital and
transcardially perfused with 50 ml 0.9% saline containing 0.1% heparin
followed by perfusion with 80 ml 4% paraformaldehyde in PBS (0.1 M;
pH 7.4). The brains were removed from the skull and post-ﬁxed by
immersion in the same ﬁxative overnight at 4 °C. After cryoprotection
in 30% sucrose in 0.1 M PBS for 3 days, the brains were snap-frozen inn-hexane at −68 °C and stored at −20 °C. Coronal sections (30 μm)
were cut on a sliding microtome and collected in 0.1 M PBS.
In order to perform qPCRmicewere sacriﬁced, brainswere removed
from the skull and subsequently neocortex, hippocampus and ventral
brainwere dissected. Dissection of the ventral brainwasdoneby cutting
off the rostral part of the brain at the level of the anterior commissure,
followed by removal of the overlaying neocortex, hippocampus and
cerebellum. Thus, it contains subcortical nuclei and hypothalamus
with well-described QC and TRH expression.
2.3. Immunohistochemical labeling
In order to perform immunohistochemistry, mouse brain slices were
pre-treated with 60% methanol (30 min), followed by washes in 0.1 M
TBS and blocked in TBS containing 0.3% TritonX-100 and 5% normal
donkey serum for 30 min to reduce unspeciﬁc binding of antibodies.
Incubation with primary antibodies was performed in TBS containing
0.1% TritonX-100 and 5% normal donkey serum over 1–3 days at 4 °C.
For detection of QC a rabbit anti-mouse QC antibody (AB1301,
Probiodrug AG, Halle/Saale, Germany) or goat anti-mouse QC antibody
(10269, Probiodrug AG)was used as described earlier [13,14]. Immuno-
histochemical labeling of TRHwasobtainedwith different commercially
available rabbit anti-TRH antibodies raised either against proTRH
(BP5066, Acris) or against synthetic pGlu-His-Pro conjugated to KLH
(PAB13482, Abnova; TRH, BioLogo). Staining with these antibodies
displayed a very similar pattern of ﬁbers and single neurons in mouse
hypothalamus indicating speciﬁc labeling since this brain region is de-
scribed to show robust TRH immunoreactivity [22]. pGlu-Aβ peptides
in mouse hippocampus were detected using the mouse monoclonal
antibody mab2-48 (Synaptic Systems, Göttingen, Germany), which
has been well characterized [42]. A goat anti-GFAP antibody (Santa
Cruz) was used for labeling of astroglia. According to the host species
of the primary antibody appropriate secondary antibodies (Dianova)
were used to visualize respective antigens either with chromogen
(3,3′DAB) or ﬂuorescent dyes (Cy2, Cy3, Cy5).
2.4. Confocal laser scanning microscopy
Laser scanning microscopy (LSM 510, Zeiss, Oberkochen, Germany)
was performed to analyze co-localization of QC and TRH in mouse
brain tissue. For Cy2-labeled antigens (green ﬂuorescence), an argon
laser with 488 nm excitation was used and emission from Cy2 was
recorded at 510 nm applying a low-range band pass (505–550 nm).
For Cy3-labeled antigens (red ﬂuorescence), a helium–neon laser with
543 nm excitation was used and emission from Cy3 at 570 nmwas de-
tected applying high-range band pass (560–615 nm). The Cy5-labeled
antigens were visualized using excitation at 650 nm and emission at
670 nm.
2.5. Stimulation of cultured primary astrocytes
Astrocyte primary cell cultures were started with brains of newborn
mice according to Löffner et al. [43] and were maintained in DMEM-
based medium at 37 °C in a humidiﬁed atmosphere with 95% air/5%
CO2. The medium was renewed once a week.
Activation of astrocyteswas inducedwhen cells had reached 80–90%
conﬂuency by incubationwith (i) Aβ1–42 (5 μM) or (ii) lipopolysaccha-
ride derived from Escherichia coli (LPS; 1 μg/ml; O55:B5, Sigma) and
interferon-γ (IFN-γ; 20 ng/ml; Preprotech) for 48 h. Cell viability was
analyzed with a commercially available lactate dehydrogenase assay
kit from Promega.
2.6. mRNA quantiﬁcation by qPCR
RNA was isolated using the NucleoSpin RNA II kit (Macherey Nagel,
Düren, Germany) according to the manufacturer's instructions. RNA
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primary astrocytes. The RNA concentration was measured using a
NanoDrop 2000 spectrophotometer (Peqlab, Erlangen, Germany). RNA
(0.1–1 mg) was reverse transcribed into cDNA using random primers
(Roche, Penzberg, Germany) and Superscript III (Life Technologies).
Quantitative PCR was performed in a Rotorgene 3000 (Corbett
Research, Sydney, Australia) using the Rotor-Gene SYBR Green PCR kit
and speciﬁc primers for QC (NM_027455.2, 5′-GGGAGGCAGACACAAT
CAAT and 3′-TCAGATTCCCAGCTGTCAGA), TRH (NM_009426.2, 5′-
GTGCCAACCAAGACAAGGAT and 3′-TTCTTCCCAGCTTCTTTGGA) and
GFAP (NM_010277.3, 5′-ACATCGAGATCGCCACCTAC and 3′-TCACATCA
CCACGTCCTTGT) synthesized by Metabion (Martinsried, Germany).
Relative gene expressionwas determined using the Rotorgene Software
version 6.1 in comparative quantitation mode. TTl (NM_027192.2),
Umps (NM_009471.2) and Sys1 (NM_025575.3) were used as reference
genes for expression analysis. The PCR was veriﬁed by product melting
curves and single amplicons were conﬁrmed by agarose gel
electrophoresis.
2.7. Quantiﬁcation of immunocytochemistry
After treatment of primary astrocytes, cells were ﬁxed in 4%
paraformaldehyde, labeled with antibodies against TRH and QC as
described in 2.3 and cell nuclei were counterstained with Hoechst
dye (1:10,000; Invitrogen). From each sample 5 images were taken
by means of ﬂuorescence microscope (Keyence Biorevo BZ-9000)
and approx. 10 cells/sample were densitometrically analyzed by
Keyence BZ-9000 Analyzer software. Values obtained from control
astrocytes were set to 100%.
2.8. Statistical analyses
Data that were obtained from qPCR experiments were analyzed
by GraphPad Prism4 Software with respect to statistical signiﬁcance in
Student's t-test and correlation analysis of data was performed with
Pearson's correlation coefﬁcient.Fig. 1. QC and TRH co-localization in hippocampal neurons of adult wild type mice. Immunohis
munoreactive neurons in distinct layers of the hippocampus. The staining displayed a similar d
stratum radiatum (rad) of the hippocampus. In the polymorphic cell layer of dentate gyrus (po)
cell layer of the hippocampus (pyr) aswell as in the granular cell layer of dentate gyrus (gr) no s
and TRH in a subpopulation of hippocampal interneurons (C). Abbreviations or, stratum oriens
molecular layer of dentate gyrus; po, polymorphic cell layer of dentate gyrus; gr, granular cell la3. Results
3.1. Co-localization of QC and TRH in hippocampus of wild type mice
In order to obtain insight into the biological signiﬁcance of the QC
expression in the hippocampus as reported by Hartlage-Rübsamen
et al. [13], we focused on the hypothalamic QC substrate TRH, since
this well known releasing hormone of the HPT axis has also been
shown to play a role in the hippocampus [33–35]. Therefore, immuno-
histochemistry was used to reveal the cellular expression pattern of
TRH in the hippocampus of young adult postnatal day 42 wild type
mice.
Immunohistochemical labelings displayed a considerable number of
TRH positive interneurons dispersed over different layers of the hippo-
campus (Fig. 1B). The regional expression pattern strongly resembled
the distribution of QC positive neurons, particularly in stratum
lacunosum moleculare and in stratum radiatum of hippocampus proper
(Fig. 1A). In the polymorphic cell layer of dentate gyrus TRH immunore-
activity was low in labeling intensity compared to the relatively strong
QC labeling. Double immunoﬂuorescent staining demonstrated co-
localization of QC and its substrate TRH in a subpopulation of hippocam-
pal interneurons (Fig. 1C).3.2. Temporal expression pattern of QC and TRH mRNA in different brain
regions during aging of Tg2576 mice
QCwas shown to be involved in the development of Aβpathology by
modifying N-terminally truncated Aβ peptides. The resulting pGlu-Aβ
peptides exhibit altered biochemical properties which lead to increased
neurotoxicity. TRH, a known hypothalamic substrate of QC, was demon-
strated to have neuromodulatory properties in the hippocampus and to
provide protection towards Aβ-mediated neurotoxicity aswell as gluta-
matergic excitotoxicity. In order to study the interrelationship between
TRH and QC we investigated the temporal gene expression pattern of
these two proteins in Tg2576 mice before and after the onset of Aβ
pathology and compared to non-transgenic littermates.tochemistry for QC (A) and TRH (B) in hippocampal slices of wild type mice revealed im-
istribution of QC- and TRH-positive neurons in stratum lacunosum moleculare (lac) and in
strong labeling for QC occurred whereas TRH immunoreactivity was low. In the pyramidal
peciﬁc labelingwas detected (A, B). Double immunolabeling revealed co-localization of QC
; lac, stratum lacunosum moleculare; rad, stratum radiatum; pyr, pyramidal cell layer; mol,
yer of dentate gyrus.
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of different age groups (4, 8, 13 and 17 months) were quantiﬁed in
distinct brain regions (ventral brain, cortex and hippocampus).
Adult Tg2576 mice at the age of 4 months were used as control and
8-month-old Tg2576 mice were chosen since at this age excitotoxicity
might be present due to the generation of high amounts of Aβ, whereas
aggregated Aβ is ﬁrst detectable in entorhinal cortex from 10 months
on. In 13-month-old Tg2576 mice numerous Aβ deposits are already
present in cortical areas, whereas Aβ plaque burden in hippocampus
is still low. This allows studying in parallel a direct effect of ongoing
Aβ deposition in two different brain areas affected by Aβ pathology.
At the age of 17 months, in cortex as well as in hippocampus of
Tg2576 mice high amounts of Aβ plaques are detectable, contrary
to the ventral brain area where hardly any plaque pathology is
detectable.
In the ventral brain, we observed an opposing trend comparing the
age-related expression of QC and TRH mRNA of Tg2576 and wild type
mice (Fig. 2). This was demonstrated by a constant decline of the
amount of QC and TRH mRNA in Tg2576 mice from 4 months up to 17
months of age, whereas in wild type littermates both gene transcripts
continuously increased from 8months onwards. As a result, expression
of QC (−67%) and TRHmRNA (−75%) in the ventral brain of 17months
old Tg2576 mice is signiﬁcantly lower compared to wild type mice
(Fig. 2).
In contrast, the neocortex, a region strongly affected byAβpathology
displayed a signiﬁcant increase of about 35% in the expression of QC
mRNA in 17-month-old Tg2576 mice (Fig. 2). In the hippocampus ex-
pression of QC and TRH mRNA remained constant over all investigated
ages revealing different expression patterns of QC and TRH mRNA in
brain areas strongly affected by Aβ pathology compared to the ventral
brain which hardly develops Aβ plaques (Fig. 2).Fig. 2. QC and TRH mRNA quantiﬁcation in distinct brain regions of Tg2576 mice aged betw
(containing hypothalamus), neocortex and hippocampus of Tg2576mice and their wild type lit
of QC and TRH in the course of aggravating Aβ pathology. With regard to the expression of QC a
was observed. QC and TRH mRNA levels were increasing from 8 months onwards in wild ty
continuous decrease of both investigated gene transcripts resulting in a signiﬁcant lowered exp
in neocortex of 17 months old Tg2576 mice with distinct Aβ pathology the expression of QC m
from 4months to 17monthswithout signiﬁcant variants. Also in the hippocampus of the inves
showed a constant level. Mean values (n= 6) are indicated as ratio of 4 months wild type (=1
are indicated by asterisks (*p b 0.5; **p b 0.01; ***p b 0.001).3.3. Correlation of QC and TRH mRNA expression in distinct brain regions
Data from QC and TRH mRNA quantiﬁcation were analyzed regard-
ing a possible correlation between the enzyme and its substrate. For
the correlation analyses, values of wild type or Tg2576 littermates
aged between 4 and 17months (n= 24)were combined and displayed
with respect to the distinct brain areas ventral brain, neocortex and
hippocampus (Fig. 3).
For the ventral brain, containing hypothalamus with well-described
expression of QC and TRH, a strong correlation between QC and TRH
mRNA levels was observed, whereas in neocortex no such correlation
was detected (Fig. 3). Interestingly, in the hippocampus of Tg2576
mice, but not of wild type littermates, the expression of QC and TRH
mRNAwas signiﬁcantly correlated (Fig. 3). Thus, regarding the develop-
ment of Aβ pathology there is evidence for a role of QC and its substrate
TRH in the hippocampus.
3.4. Reactive astrocytes around Aβ deposits in Tg2576mice are QC and TRH
immunoreactive
Since the quantiﬁcation of QC and TRHmRNA provided evidence for
a regulation of TRH by Aβ pathology, we asked whether the hippocam-
pal expression of TRH on the protein level might also be altered.
Interestingly, TRH immunohistochemistry of Tg2576 mice aged
between 4 and 21 months revealed astrocytic TRH immunoreactivity in
close proximity to Aβ plaques of older animals. In cortical and in hippo-
campal areas of Tg2576 mice Aβ plaques are detectable at about 10 and
13 months of age, respectively. The appearance of TRH-positive astro-
cytes correlated with the age-dependent development of Aβ plaques in
neocortex (10 months) and hippocampus (13 months) of these human
APP-transgenic mice (Fig. 4A). Furthermore, TRH-immunoreactiveeen 4 and 17 months. Expression of QC and TRH mRNA was analyzed in ventral brain
termates. Mice aged between 4 and 17monthswere used in order to study the expression
nd TRHmRNA in the ventral brain an opposing trend in Tg2576 and wild type littermates
pe mice. In contrast, in Tg2576 mice we observed from 4 months to 17 months of age a
ression at the age of 17 months compared to their wild type littermates. On the contrary,
RNA was signiﬁcantly increased and the expression of TRH mRNA displayed a stable level
tigated Tg2576 and their wild type littermates the expression proﬁle of QC and TRHmRNA
00%, arbitrary units (a. u.)), statistical differences were analyzed using Student's t-test and
Fig. 3. Correlation of QC and TRHmRNA expression in distinct brain regions of Tg2576mice. Correlation analysis revealed a strong interdependence of QC and TRHmRNA expression in the
ventral brain of, both, Tg2576mice and their non transgenic littermates as well as a signiﬁcant correlation in the hippocampus of Tg2576 but not of wild type animals. No correlation was
measured in the neocortex. For correlation analysis mRNA values of all mice of the indicated genotype aged between 4 and 17months were combined (n= 24 each). Pearson correlation
coefﬁcient r and p values (*p b 0.5; **p b 0.01; ***p b 0.001) are indicated in the diagrams.
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cal characteristics of activated astroglia such as enlarged somata and
processes (Fig. 4A). This distinct glia-like TRH stainingwas not observed
distant from Aβ plaques.
3.5. QC and TRH are co-localized in activated astrocytes in Tg2576 mice
Double immunoﬂuorescent labelings for GFAP and pGlu-Aβ in
hippocampal brain slices of 17 months old Tg2576 mice conﬁrmed the
activation of astrocytes around Aβ plaques (Fig. 4B). Reactive astrocytes
in proximity to plaques but not in astrocytes away from Aβ deposits
were found to be pGlu-Aβ immunoreactive (Fig. 4B). Similarly, Aβ
plaque-associated reactive astrocytes also displayed TRH immunoreactiv-
ity (Fig. 4C). Both products of the enzymatic activity of QC, TRH and pGlu-
Aβ, were found to be co-localized with QC in Aβ plaque-associated reac-
tive astrocytes (Fig. 4D). Thus, there is a distinct induction of QC, TRH and
pGlu-Aβ in plaque-associated reactive astrocytes.
3.6. Expression of QC and TRH in cultures of primary astrocytes upon Aβ
treatment
As described above, we observed activated astrocytes surrounding
Aβ plaques of Tg2576 mice which show co-expression of QC and TRH.
In order to reveal whether Aβ peptides directly mediate the induction
of QC and TRH in reactive astrocyteswe used a primarymouse astrocyte
cell model. Primary astrocytes were stimulated with Aβ or a general
pro-inﬂammatory mixture of LPS/IFN-γ and the expression of QC and
TRH mRNA as well as immunoreactivity for QC and TRH protein was
studied after a 48 h stimulation period. Compared to vehicle-treated as-
trocytes, the expression of QC mRNA was increased by 23% (p b 0.05)
upon Aβ stimulation, whereas the 15% increase in TRH mRNA levels
was not statistically signiﬁcant (Fig. 5A). Immunocytochemical labeling
of QC and TRH also suggested increased protein levels (Fig. 5B). Quanti-
tative image analysis demonstrated increased QC (+65%; p b 0.01) and
for TRH (+57%; p b 0.05) protein levels (Fig. 5A). This indicates that aprimary Aβ-induced increase in QC mRNA and protein expression
results in the stabilization and, therefore, increased concentration of
the QC substrate TRH without signiﬁcant change in its mRNA level. In
contrast, a general pro-inﬂammatory stimulation of astrocytes with
LPS/IFN-γ did not induce QC or TRH mRNA or protein levels (not
shown).
4. Discussion
In the 1990s, new Aβ peptide variants were identiﬁed comprising
N-terminally truncated andpGlu-modiﬁed species. TheseAβ variants dis-
play altered biochemical, biophysical and cell biological properties leading
to enhanced neurotoxicity and resistance to proteolytical degradation.
The enzyme QC was demonstrated to catalyze the pGlu modiﬁcation of
Aβ andpharmacological QC inhibition in Tg2576mice resulted in a reduc-
tion of Aβ plaque burden [12]. However, when using QC inhibition as
pharmacological tool for AD treatment, it is important to understand
the physiological function of QC expression.
In a previous report, we alreadymapped regional and cellular QC ex-
pression in wild type mouse brain and identiﬁed QC-immunoreactive
interneurons in distinct layers of the hippocampus [13]. The neurohor-
mone TRH is known to be an important physiological QC substrate in
diencephalon where both, enzyme and substrate, are expressed by
neurons of the paraventricular nucleus of the hypothalamus. Studies
concerning an alternative TRH function as neurotransmitter and
neuromodulator in the hippocampus [25,28,34,35] prompted us to
relate TRH to QC expression in this brain region.
Here, we report for the ﬁrst time co-localization of QC and TRH in a
neuronal subpopulation of the hippocampus in adult wild type mice.
However, since not all QC expressing neuronswere positive for TRH im-
munoreactivity, it is very likely that other, yet unknown QC substrates
exist in the hippocampus. Our ﬁnding conﬁrms previous reports that
demonstrated intrinsic TRH expression in the hippocampus, albeit
most hippocampal TRH is supposed to derive from extrinsic sources
[26]. When pathological amounts of Aβ peptides are present in AD, QC
Fig. 4.Age-dependent increase of astrocytic QC and TRH immunoreactivity in the vicinity of Aβ-deposits in the neocortex and hippocampus of Tg2576mice. Tg2576mice develop deposits
of aggregated Aβ in cortex and hippocampus from 10 and 17 months onwards, respectively. For analysis of TRH immunoreactivity Tg2576mice aged between 4 and 21months were ex-
amined. (A) Immunohistochemistry revealed TRH staining in astrocytes that encircle Aβ deposits in cortex and hippocampus of Tg2576mice at 10 and 17months, respectively (asterisks).
The increasing number of TRH-positive astrocytes was associated with age and thereby the quantity of Aβ deposits. Tg2576 mice without apparent Aβ aggregates (4 months old) were
devoid of TRH-positive astrocytes. (B) The density of GFAP-immunoreactive astrocytes (red) around pGlu-Aβ deposits (green, asterisk) is increased and their morphology is altered to
a reactive phenotype. Some of the Aβ plaque-associated astrocytes (within the white circle) display pGlu-Aβ immunoreactivity (arrows), as indicated by yellow/orange color. Astrocytes
distant from Aβ deposits (outside thewhite circle) do not display pGlu-Aβ immunoreactivity. (C) Aβ plaque-associated astrocytes (red) are also immunoreactive for TRH (green, arrows).
The location of Aβ deposits is marked by asterisks. Astrocytes distant from Aβ deposits, outside the circle, are not TRH-immunoreactive (arrowheads). (D) Both products of the enzymatic
activity of QC, TRH (red) and pGlu-Aβ (blue, asterisk), and QC itself (green) are co-localized in Aβ plaque-associated reactive astrocytes (arrows) as indicated bywhite color in the overlay
channel.
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the intracellular modiﬁcation of Aβ resulting in highly neurotoxic
pGlu-Aβ. Such a degeneration of QC expressing interneurons could re-
sult in the release of pGlu-Aβ acting as a seed for further Aβ aggregation[9] and to a decrease of TRH concentration in the hippocampus as it was
demonstrated in post mortem brains of AD [41]. Regarding the neuro-
protective ability of TRH to counteract Aβ-induced neurodegeneration
[39,40] as well as excitotoxicity in cell culture models [31–33], the
Fig. 5. Expression of QC and TRH in primary astrocytes. Cultured primary astrocytes were
activated by incubation with Aβ (5 μM) for 48 h. (A) Quantitative RT-PCR revealed an in-
crease in QC mRNA in Aβ-stimulated astrocytes (black bars) by 23% (p b 0.05), whereas
TRH mRNA levels remained unchanged (n = 6). Moreover, protein levels for QC and
TRHwere increased by 65 and 57%, respectively as revealed by quantitative immunocyto-
chemistry. Mean values for treated astrocytes are given as per cent of untreated value
(=100%). Statistical differences were analyzed using Student's t-test and are indicated
by asterisks (*p b 0.5). (B) Examples of immunocytochemical ﬂuorescent labelings of as-
trocytes for QC (green) and TRH (red) under control conditions and after Aβ stimulation.
Note the robust increase in the staining intensity after Aβ stimulation in a high proportion
of the astrocytes (arrows). Cellular nuclei are stained with Hoechst dye (blue).
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pathological processes in AD. Also, in Parkinson's disease [36,37] and in
the context of CNS trauma [38,39] neuroprotective effects of TRH were
reported.
In order to study the regional expression of QC and TRHwith regard
to Aβ pathology, we compared Tg2576 mice with wild type littermates
at different postnatal ages using quantitative PCR aswell as immunohis-
tochemistry. We detected a signiﬁcantly higher expression of QCmRNA
only in the neocortex of 17-month-old transgenic mice with substantial
Aβ pathology which could account for the enhanced formation ofpGlu-Aβ deposits as revealed by immunohistochemistry. In contrast,
unchanged QC mRNA levels in the hippocampus of Tg2576 mice could
be related to the delayed development of Aβ pathology in this brain re-
gion. In the hippocampus aswell as in the neocortexwe did not observe
signiﬁcant differences in the expression of TRH mRNA in Tg2576 mice
compared to wild type littermates. In the light of the induction of
QC and TRH protein in reactive astrocytes of aged Tg2576 mice (see
below), increased levels of these transcripts might be expected. This
discrepancymay be explained by a dissociation between the regulation
of mRNA and protein expression and/or a reduction of neuronal QC and
TRHmRNAexpression in parallelwith the induction of these transcripts
in reactive astrocytes.
On the other hand, diminished TRH protein levels were reported for
hippocampus in AD [41]. Since we observed constant hippocampal TRH
mRNA levels and an induction of TRH protein in reactive astrocytes of
aged Tg2576 mice, our ﬁndings point towards differences between the
transgenic animal model and the human disease. For example, human
brain samples analyzed always reﬂect the ﬁnal stage of the disease,
the post mortem delay is much longer than in animal studies and the
mouse model used only mimics aspects of the human disease.
A correlation analysis revealed a signiﬁcant correlation between QC
and TRHmRNA in the hippocampus of Tg2576mice but not ofwild type
mice pointing to an effect of developing Aβ pathology on the expression
of QC and TRH.
To study the expression of QC and TRH in a part of the brain,which is
less affected byAβ pathology,we used tissue of the ventral brain includ-
ing the hypothalamus amongst other subcortical nuclei. In this part of
the brain, the mRNA expression of both, QC and its substrate TRH, was
signiﬁcantly decreased in 17-month-old Tg2576 mice compared to
wild type littermates. Most TRH is synthesized in the paraventricular
nucleus of the hypothalamus, which projects— apart from the pituitary
gland — also to the hippocampus [44], brain stem [45] and spinal cord
[46]. A decrease in the release of hypothalamus-derived TRH could
therefore impair TRH-mediated neuromodulation as well as HPT axis,
the latter being affected in AD patients as reported by Yong-Hong
et al. [47]. Vice versa, hippocampal Aβ pathology may in a retrograde
manner affect hypothalamic afferents. In Tg2576 mice devoid of hypo-
thalamic Aβ pathology, hypothalamicmetabolic andhormonal dysfunc-
tion have been reported [48,49] which may by the basis for the effects
observed here on TRH and QC mRNA expression.
Since determination of mRNA expression is not sufﬁcient to gain
insight in cellular expression, immunohistochemical stainings were
performed. In order to obtain more information about pronounced
state of pathology in hippocampus, we decided to use brain slices of
Tg2576 mice aged between 4 and 21 months for immunohistochemis-
try, because qPCR experiments revealed signiﬁcant differences in
mRNA expression levels particularly in 17-month-oldmicewith distinct
Aβ pathology.
Interestingly, we did not observe any obvious alteration in the num-
ber of QC and TRHpositive neurons (not shown), but detected induction
of strong TRH labeling of astrocytes in close proximity to Aβ plaques.
Furthermore, QC, the enzyme which converts TRH into its bioactive
state, was co-localized with its substrate in activated astrocytes. We
consider this as being strong evidence for an intracellular production
of biologically active TRH in astrocytes. However, we cannot completely
rule out the possibility that the observed immunoreactivity is caused
by endocytosis of neuronally secreted TRH. Although the expression
and processing of neuropeptides by astroglia is still controversially
discussed, there is some evidence supporting this hypothesis. For exam-
ple, astrocyteswere shown to express enzymes that are involved in pro-
TRH processing like carboxypeptidase C/D [50,51] and peptidyl-glycine
alpha-amidating monooxygenase [52]. Recently, spinal astrocytes were
demonstrated to process prodynorphin and release dynorphin [53]
indicating that astrocytes are principally able to process pro-peptides.
In addition, a glioblastoma cell line was shown to release TRH [54]
and with respect to cultured astrocytes, earlier publications already
Fig. 6. Potential relevance of hippocampal QC and TRH under physiological and pathological conditions. Under physiological conditions hippocampal interneurons co-express QC and TRH
and contribute to LTP modulation and neuroprotection by releasing TRH. However, under pathological conditions in AD, QC-catalyzed pGlu-Aβ generation induces degeneration of these
interneurons. This results in diminished release of neuroprotective TRH and presumably in altered neuromodulation and increased excitotoxicity. Furthermore, the formation of Aβ
plaques as well as neurodegeneration induces the activation of astrocytes. The co-induction of QC and TRH in reactive astrocytes could contribute to TRH-mediated neuroprotection as
well as to further neurodegeneration by generation of astrocyte-derived pGlu-Aβ.
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of TRH in medium [55].
Furthermore, in performing qPCR on mouse primary astrocytes
we detected substantial expression of TRH mRNA and QC mRNA. The
transcript levels of QC and protein concentrations of QC and TRH were
increased upon stimulation with Aβ. The elevated TRH protein concen-
tration without induction of the corresponding mRNA suggests post-
translational pGlu modiﬁcation and, thereby, stabilization of TRH by
QC. On the other hand, the stimulation of cultured astrocytes with LPS
and IFN-γ did not modulate QC or TRH mRNA or protein expression.
This is strong evidence for Aβ peptides themselves — and not other
factors present in or around Aβ deposits — being triggers for astrocytic
QC and TRH expression. Since we also observed strong TRH immunore-
activity in astrocytes enclosing Aβ plaques in Tg2576mice, it is conceiv-
able, that it is due to a chronic, Aβ-mediated activation of astrocytes in
these AD model mice.
The ﬁnding of QC and TRH in activated astrocytesmight be of impor-
tance with regard to a role of astroglia contributing to AD pathogenesis.
Since astrocytes were demonstrated to express the β-secretase BACE1
[56,57], the additional expression of QC provides the possibility of
astroglial derived toxic pGlu-Aβ leading to astrogliosis and the forma-
tion of Aβ plaques. Moreover, astrocytes are involved in maintaining a
stable extracellular milieu for proper neuronal functioning and excit-
ability. For example, astrocytes express speciﬁc glutamate transporters
to avoid excessive extracellular concentrations of glutamate that could
induce excitotoxicity [58]. In this context, a function of TRH is discussed
in reducing the neuronal release of glutamate [34], thereby modulating
neuronal activity andpresumably diminishing excitotoxicity. Astrocytes
were also shown to express receptors for leptin [59,60] which is well-
known to increase TRH expression [61]. For leptin, a role in AD pathol-
ogy has been discussed by inﬂuencing the composition of membrane
lipid rafts and thereby the activity of BACE1 [62–64].5. Conclusions
This is the ﬁrst demonstration of (i) a neuronal co-localization of QC
and TRH in hippocampus, (ii) distinct differences in QC and TRH mRNA
expression in brain regions with and without Aβ pathology in Tg2576
mice and (iii) astroglial co-expression of QC and TRH in the vicinity of
Aβ plaques in the hippocampus. Functionally, the expression of QC in
astrocytes could play a role in neuroprotection by the activation and
release of TRH, thereby reducing excitotoxicity but also in neurodegen-
eration due to the formation of pGlu-Aβ (Fig. 6). With regard to QC as a
therapeutical target for pharmacological inhibition in AD, our resultssuggest that a potential decrease of a neuroprotective TRH effects
would be compensated by the beneﬁts of a reduction in Aβ pathology.
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